C. Ola Landgren, MD, PhD
The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further, according to C. Ola Landgren, MD, PhD.
In an interview during the meeting, Landgren, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, picks apart some of the top presented abstracts in multiple myeloma from the 2016 ASH Annual Meeting, as well as what’s in store for the field.
OncLive: Can you provide an overview of your lecture in myeloma?
: It included selected highlights from the 2016 ASH Annual Meeting. I first talked about the updated CASTOR and POLLUX studies that are based on daratumumab, both in combination with lenalidomide/dexamethasone and bortezomib/dexamethasone in the 2 studies, respectively. These combos were recently FDA approved for patients with 1 or more prior lines of therapy.
The third is the use of venetoclax, an oral BCL-2 inhibitor. It was recently approved for other B-cell malignancies. There was updated information on single-drug use in a phase I trial for patents with myeloma. In patients with an 11;14 translocation who typically have activation of BCL-2, they seem to have pretty good response to this drug.
We have heard about the POLLUX/CASTOR studies often. What questions still need to be answered regarding those studies?
It is very exciting to see how the monoclonal antibodies are coming at full speed into the myeloma field. The FDA approved the use of daratumumab as a single agent in November 2015 and now the agency gave approval of daratumumab in combination with lenalidomide/dexamethasone and bortezomib/dexamethasone, which is exactly what the CASTOR and POLLUX studies show.
... to read the full story